Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates autologous dendritic cell vaccine therapy plus the standard of care for advanced renal cell carcinoma (RCC), and compares these data to results from the CARMENA trial (NCT00930033). This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.Robert Figlin, MD, of Cedars-Sinai Medical Center, Los Angeles, CA, gives an update on the ADAPT trial (NCT01582672), which investigates autologous dendritic cell vaccine therapy plus the standard of care for advanced renal cell carcinoma (RCC), and compares these data to results from the CARMENA trial (NCT00930033). This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Patient selection is crucial for vaccine therapy success in kidney cancer
